Jiwon Oh, AAN 2022: Tolebrutinib as a potential treatment in relapsing multiple sclerosis – Long-term extension study, phase 2b, 18-month results
Tolebrutinib is an oral, CNS-penetrant Bruton’s tyrosine kinase inhibitor with dual mechanism of action: peripheral B cell modulation and re-establishment of CNS microglial homeostasis. Dr Jiwon Oh (St. Michael’s Hospital, University of Toronto, Canada) joins us to discuss the phase 2b trial (NCT03889639), investigating safety and efficacy of tolebrutinib in patients with relapsing multiple sclerosis.
The abstract entitled ‘Safety and Clinical Efficacy Outcomes From the Long-term Extension Study of Tolebrutinib in Patients With Relapsing Multiple Sclerosis: 18-Month Results’ was presented at the American Academy of Neurology (AAN) annual meeting, April 2-7, 2022.
- What is tolebrutinib and what are its potential advantages over existing therapies in the treatment of patients with relapsing multiple sclerosis (MS)? (0:15)
- What did the Phase 2 study teach us about the efficacy and safety of tolebrutinib in this indication? (2:37)
- What will be the next step in the clinical development of tolebrutinib? (4:53)
Disclosures: Jiwon Oh is a consultant and is on the advisory board for Sanofi-Genzyme, and also receives honoraria/honorarium from Sanofi-Genzyme.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Neuroimmunology
Michael Levy: Highlights from the 75th AAN Annual Meeting, 2023
Dr Michael Levy (Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA) provides his highlights from the 75th AAN Annual Meeting, 2023, in particular that this was the first year to have a myelin oligodendrocyte glycoprotein (MOG) antibody disease focus, with posters on two phase 3 trials, which are expected to be presented in 2026. Disclosures: […]
Michael Levy, AAN 2023: Phase 3 CHAMPION-NMOSD subgroup analyses in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
CHAMPION-NMOSD (NCT04201262) is a study of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Ravulizumab binds to the same complement component 5 epitope as eculizumab; however, its longer elimination half-life extends the dosing interval (every 8 versus 2 weeks). In this touchNEUROLOGY interview, we caught up with Dr Michael Levy (Massachusetts General Hospital, […]
Sean Pittock, ECTRIMS 2022: Subgroup analyses from the phase 3 CHAMPION-NMOSD investigating ravulizumab for neuromyelitis optica spectrum disorder
The CHAMPION-NMOSD trial (NCT04201262) is a global, open-label, multicentre, phase 3, externally controlled study of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD). In this touchNEUROLOGY interview, we caught up with Prof. Sean Pittock (Mayo Clinic, Rochester, MN, USA) to discuss the pre-specified efficacy analyses in clinically relevant patient subgroups, and the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!